Bio-Techne Corporation
Every calculator, already run for TECH
Open the full toolkit →You have the numbers on TECH. Get the argument.
A written report on which of these readings actually decide the outcome for Bio-Techne Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering TECHAnalyst Price Target Disagreement for Bio-Techne Corporation
Wall Street's bull case implies +1% from the current price; the bear case implies -31%. A 32% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for TECH
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists…
TECH — frequently asked
Is TECH a buy right now?
Wall Street's consensus rating on Bio-Techne Corporation is none across 14 analysts, with a mean price target of $70.73 (-3% vs. the current $72.55). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is TECH overvalued?
TECH trades at 62.5x trailing earnings, against a DCF fair value of $24 per share. The current price implies 21% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is TECH's next earnings date?
Bio-Techne Corporation is next scheduled to report earnings around Nov 9, 2026. A full TECH research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Bio-Techne Corporation?
Analysts covering Bio-Techne Corporation (TECH) range from a bear-case target of $50.00 to a bull-case high of $73.00, with a mean consensus target of $70.73 across 11 analysts. The spread of $23.00 (32% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Bio-Techne Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Bio-Techne Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TECH research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Bio-Techne Corporation, in minutes. 3 free reports included with every account — no credit card required.